0 Evotec AG Analyst Ratings, Earnings, Dividends and Insider Trades | $EVTC | NASDAQ:EVTC | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Evotec AG Company Profile (NASDAQ:EVTC) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Evotec AG (NASDAQ:EVTC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)Consensus Rating:Buy (Score: 2.88)Consensus Price Target: $26.50 (6.30% upside) Analysts' Ratings History for Evotec AG (NASDAQ:EVTC) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/13/2014Morgan StanleyReiterated RatingEqual Weight$26.00 -> $24.00View 12/24/2013Stifel NicolausInitiated CoverageBuy$27.00View 9/16/2013Bank of AmericaInitiated CoverageBuyView 9/16/2013Bank of AmericaInitiated CoverageBuyView 8/9/2013Deutsche BankBoost Price Target$25.00 -> $28.00View 8/9/2013Credit SuisseBoost Price TargetOutperform$25.00 -> $27.00View 8/8/2013UBS AGBoost Price TargetBuy$27.00 -> $28.00View 8/8/2013Deutsche BankReiterated RatingBuyView 8/8/2013JPMorgan Chase & Co.Reiterated RatingOverweightView 8/8/2013Morgan StanleyDowngradeOverweight -> Equal WeightView 5/7/2013William BlairInitiated CoverageOutperformView 5/7/2013UBS AGInitiated CoverageBuy -> Buy$24.00View 5/7/2013Credit SuisseInitiated CoverageOutperform$25.00View 5/7/2013Deutsche BankInitiated CoverageBuy$25.00View 5/7/2013Goldman SachsInitiated CoverageBuy$25.00View 5/7/2013Bank of AmericaInitiated CoverageBuy$25.00View 5/7/2013JPMorgan Chase & Co.Initiated CoverageOverweightView 5/7/2013Morgan StanleyInitiated CoverageOverweight$23.00View (Data available from 3/8/2012 forward) Earnings History for Evotec AG (NASDAQ:EVTC)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/12/2014Q413$0.00$0.43$91.00 million$93.30 millionViewN/AView 11/6/2013Q313$0.00$0.36$83.80 million$87.40 millionViewN/AView 8/7/2013Q2 2013$0.00$0.35$84.40 million$89.20 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Evotec AG (NASDAQ:EVTC)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare2/12/2014quarterly$0.102/21/20142/25/20143/14/2014 11/6/2013quarterly$0.1011/14/201311/18/201312/6/2013 8/8/2013special$0.108/15/20138/19/20139/6/2013 8/7/2013quarterly$0.108/19/20139/6/2013 (Data available from 1/1/2013 forward) Insider Trading History for Evotec AG (NASDAQ:EVTC)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare12/13/2013Popular IncDirectorSell5,800,000$20.33$117,914,000.00View 9/18/2013Apollo Management Holdings Gp,major shareholderSell13,808,759$21.77$300,616,683.43View 9/18/2013Carlos RamirezEVPSell30,000$21.77$653,100.00View 9/18/2013Popular IncDirectorSell9,057,000$21.77$197,170,890.00View 9/17/2013Frank D'angeloDirectorBuy10,000$22.97$229,700.00View 4/17/2013Philip E SteurerCOOBuy2,500$20.00$50,000.00View (Data available from 1/1/2013 forward) About Evotec AG Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry. In addition, the Company has a small number of its own drug candidates at various stages of development either partnered or available for partnering. It provides integrated solutions to the pharmaceutical and biotechnology industry from target to clinical development through a range of capabilities and capacities, including early-stage assay development and screening, fragment-based drug discovery through to medicinal chemistry and in vivo and in vitro pharmacology. As of December 31, 2011, its primary operating entities included the United Kingdom-based Evotec (UK) Ltd, India-based Evotec (India) Private Ltd, the United States-based Compound Focus, Inc, and two Germany-based subsidiaries Kinaxo Biotechnologies GmbH and DeveloGen AG. Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: EVTC CUSIP: Key Metrics: Previous Close: $24.8750 Day Moving Average: $24.4379200 Day Moving Average: $23.4542 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $1.952BCurrent Quarter EPS Consensus Estimate: $0.00 EPS Additional Links: View EVTC on Google FinanceView EVTC on Yahoo FinanceView EVTC's Company Profile on ReutersSearch for Evotec AG on Google Evotec AG (NASDAQ:EVTC) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.